GSK-2696277

N/A

Report date: 2024/11/08 20:00:30

Base Information

Drug NameGSK-2696277

Drug Alias NameAutologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin geneGSK-2696277OTL-300

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived +[4]

Mechanisms of ActionHemoglobin beta chain modulatorsHematopoietic progenitor cell antigen CD34 modulators

TargetsHemoglobin beta chainHematopoietic progenitor cell antigen CD34

Therapy Area/Indicationsbeta-Thalassemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryItaly

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc Ospedale San Raffaele Fondazione Telethon

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesOrchard Therapeutics Plc Fondazione Telethon

Active IndicationsN/A

Inactive Indicationsbeta-Thalassemia

Other Information

ATC CodeN/A